Miricor Enterprises Holdings Ltd (1827) AI Stock Analysis

• Market Cap: HK$280.00M
• Dividend Yield: N/A
• Average Volume (3M): 4.67K
• Price to Earnings (P/E): 44.2
• Beta (1Y): -0.21
• Revenue Growth: -20.59%
• EPS Growth: N/A
• Country: HK
• Employees: 242
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): >-0.01
• Shares Outstanding: 400,000,000
• 10 Day Avg. Volume: 6,000
• 30 Day Avg. Volume: 4,666
• PEG Ratio: -0.24
• Price to Book (P/B): 3.17
• Price to Sales (P/S): 1.16
• P/FCF Ratio: 4.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: HK$0.73 ▼(-23.68% Downside)
• Action: Upgraded Date: 01/29/26
• Date: Action: Upgraded 01/29/26

The score is primarily supported by improving profitability and strong cash-flow generation alongside reduced leverage. However, the stock is heavily penalized by weak technicals (price below key moving averages, negative MACD, very low RSI) and a relatively high P/E, while declining revenue remains a fundamental risk.

Positive Factors

Strong free cash flow generation

Sustained 31% FCF growth and very high conversion of earnings into cash (OCF/NI 4.32; FCF/NI 98.29%) provide durable internal funding. This strengthens the company’s ability to fund capex, service debt, and invest in strategic initiatives without relying on external capital over the medium term.

Improved operating and gross margins

A 52% gross margin and recovering EBIT/EBITDA show the business has regained structural cost control and pricing leverage. Even with modest net margin, improved operational efficiency reduces break-even risk and supports sustainable profitability if revenue stabilizes or grows.

Lower leverage and stronger balance sheet

A lower debt-to-equity (0.60) and a moderate equity ratio give the company greater financial flexibility and resilience to shocks. Reduced leverage decreases refinancing risk and interest burden, enabling management to prioritize growth or deleveraging with less strain on cash flow.

Negative Factors

Declining revenue trend

An ongoing revenue contraction (-11.85%) is a structural concern: it erodes scale benefits, limits operating leverage, and constrains reinvestment capacity. Without a clear revenue recovery, margin gains and cash generation risk being insufficient to drive durable growth or expand market share.

Thin net profitability

Net margin of 2.63% leaves limited buffer against cost shocks, competitive pressure, or slower sales. Even though margins improved, low absolute profitability makes earnings and cash flow vulnerable to modest adverse changes in revenue, reducing long-term resilience and ability to sustainably increase returns.

Modest return on equity

ROE of 7.18% is modest and indicates limited efficiency in converting equity into returns. Over a multi-quarter horizon this level may constrain shareholder value creation and signal that incremental reinvestment will deliver only modest returns unless revenue growth or margin expansion accelerates.

Miricor Enterprises Holdings Ltd Business Overview & Revenue Model

Company Description

Miricor Enterprises Holdings Limited, an investment holding company, provides medical aesthetic services in Hong Kong. It also offers a range of non-surgical medical aesthetic services, including energy-based and injection procedures. The company operates three medical aesthetic centers under the CosMax+ name. It also sells skin care products, such as cleansers, toners, serums, moisturizers, eye care products, ultraviolet protection products, and masks. Miricor Enterprises Holdings Limited was founded in 2009 and is headquartered in Causeway Bay, Hong Kong.

How the Company Makes Money

Miricor Enterprises generates revenue through multiple streams, primarily by commercializing its biotechnology products and services. The company earns money by selling its proprietary medical technologies and healthcare solutions to hospitals, clinics, and other healthcare providers. Additionally, Miricor may engage in partnerships and collaborations with pharmaceutical companies and research institutions, allowing it to share resources, technology, and expertise, which can lead to joint ventures and co-development agreements. This collaborative approach not only expands its market reach but also provides additional funding through shared investments. Furthermore, licensing its technologies and intellectual property to other firms in the biotech sector contributes to its revenue, while government grants and research funding for innovative projects serve as supplementary income sources.

Miricor Enterprises Holdings Ltd Financial Statement Overview

Summary

Financials are mixed but improving: cash flow is strong (free cash flow growth 31% and high cash conversion vs. net income), profitability margins have improved with net margin turning positive (2.63%), and leverage is lower (debt-to-equity 0.60). The key weakness is shrinking revenue (-11.85%), which limits the overall score.

Income Statement

Miricor Enterprises Holdings Ltd has shown a decline in revenue growth with a negative rate of -11.85% in the latest year, indicating a contraction in sales. However, the company has improved its gross profit margin to 52.37%, suggesting effective cost management. The net profit margin has turned positive at 2.63%, recovering from previous losses, which is a positive sign of profitability. The EBIT and EBITDA margins have also improved, reflecting better operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has decreased to 0.60, indicating a reduction in leverage and a more stable financial structure. Return on equity has improved to 7.18%, showing better utilization of shareholder funds. The equity ratio stands at 31.30%, suggesting a moderate level of equity financing relative to total assets, which provides a cushion against financial risks.

Cash Flow

Miricor Enterprises has achieved a strong free cash flow growth rate of 31.00%, demonstrating improved cash generation capabilities. The operating cash flow to net income ratio is 4.32, indicating robust cash flow relative to net income. The free cash flow to net income ratio is high at 98.29%, reflecting efficient conversion of earnings into cash.

Breakdown	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	403.15M	494.26M	463.12M	363.92M	128.87M
Gross Profit	211.13M	225.37M	238.23M	209.54M	44.99M
EBITDA	106.36M	86.62M	70.34M	94.02M	16.93M
Net Income	10.59M	-12.62M	-20.50M	25.38M	-12.65M
Balance Sheet
Total Assets	471.28M	479.44M	516.81M	476.81M	372.13M
Cash, Cash Equivalents and Short-Term Investments	192.17M	182.43M	179.32M	128.16M	161.77M
Total Debt	88.76M	99.75M	130.28M	127.58M	42.49M
Total Liabilities	323.72M	342.68M	366.10M	305.54M	226.56M
Stockholders Equity	147.56M	136.76M	150.71M	171.27M	145.57M
Cash Flow
Free Cash Flow	112.07M	58.24M	72.67M	-67.61M	19.07M
Operating Cash Flow	114.02M	84.45M	99.45M	44.03M	24.54M
Investing Cash Flow	-30.95M	-59.00M	-37.84M	-97.51M	52.20M
Financing Cash Flow	-50.03M	-55.59M	-21.92M	-28.73M	-14.65M

Miricor Enterprises Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1827, the sentiment is Negative. The current price of 0.95 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.86, and below the 200-day MA of 0.99, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 41.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1827.

Miricor Enterprises Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1161	73 Outperform	HK$632.91M	7.71	24.41%	5.98%	-0.19%	19.04%
1830	66 Neutral	HK$1.48B	4.60	36.52%	9.92%	-23.31%	-44.61%
8603	66 Neutral	HK$5.62B	21.31	49.25%	―	56.28%	-9.91%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
1827	57 Neutral	HK$280.00M	44.19	7.67%	―	-20.59%	―
0919	53 Neutral	HK$80.50M	2.59	10.10%	―	-3.40%	515.63%

Miricor Enterprises Holdings Ltd Corporate Events

Miricor Promotes CFO Tang Sung Kin to Executive Director Role

Miricor Enterprises Holdings Limited has appointed its current chief financial officer, Mr. Tang Sung Kin, as an executive director with effect from 30 December 2025, formalising his role in the group’s top leadership after more than two decades of experience in finance, private equity and corporate management across Hong Kong and Mainland China. Tang, a CFA charterholder and fellow of the Hong Kong Institute of Certified Public Accountants, will continue to receive his existing CFO salary without an additional director’s fee, and his appointment, governed by a service agreement running to the company’s third annual general meeting after his start date, is expected to strengthen Miricor’s governance and financial stewardship as the group seeks to leverage his capital markets and asset management background.

The most recent analyst rating on (HK:1827) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Miricor Enterprises Holdings Ltd stock, see the HK:1827 Stock Forecast page.

Miricor Sets Out Board and Committee Structure to Bolster Governance

Miricor Enterprises Holdings Limited has announced the current composition of its board of directors, listing four executive directors, including Chairlady and Chief Executive Officer Ms. Lai Ka Yee Gigi, and three independent non-executive directors. The company has also confirmed the membership and leadership structure of its three key board committees—audit, remuneration and nomination—clarifying which directors sit on each committee and who chairs them, thereby reinforcing its corporate governance framework and transparency for shareholders and regulators.

The most recent analyst rating on (HK:1827) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Miricor Enterprises Holdings Ltd stock, see the HK:1827 Stock Forecast page.